Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Identifier et catégoriser les langues minoritaires en Europe / / Joan Busquets, Sébastien Platon, Alain Viaut
| Identifier et catégoriser les langues minoritaires en Europe / / Joan Busquets, Sébastien Platon, Alain Viaut |
| Autore | Alves Carlos |
| Pubbl/distr/stampa | Pessac, : Maison des Sciences de l’Homme d’Aquitaine, 2019 |
| Descrizione fisica | 1 online resource (440 p.) |
| Altri autori (Persone) |
BertileVéronique
BlairPhilip BroderickMiriam BurbanChrystelle BuschBrigitta BusquetsJoan CilliaRudolf de EftimieAlexandra FinesFrancette GermelmannFriedrich GicquelHéloïse GootAuke van der LagardeChristian MacovieOana MarkoJoseph MassanaAntoni Milian i McKendryEugene Pérez FernándezJosé Manuel PlatonSébastien SoléAlexia Bos i SurEmmanuel ViautAlain WaltonMartin |
| Soggetto topico |
Language & Linguistics
langue régionale langue minoritaire identification catégorisation protection structuration politique histoire |
| Soggetto non controllato |
langue régionale
identification catégorisation histoire langue minoritaire protection structuration politique |
| ISBN | 2-85892-521-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | fre |
| Record Nr. | UNINA-9910350182303321 |
Alves Carlos
|
||
| Pessac, : Maison des Sciences de l’Homme d’Aquitaine, 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair
| Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair |
| Autore | O'Brien Kylie |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (xxi, 576 pages) |
| Disciplina | 615.7827 |
| Soggetto topico |
Cannabinoids - Therapeutic use
Mental illness - Treatment Cànnabis Ús terapèutic Malalties mentals |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-78559-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
1: Introduction -- Why This Book? -- The Structure of the Book -- Limitations -- Medicinal Cannabis as Part of a Holistic Therapeutic Approach -- Your Journey -- A Final Note from Dr. Blair -- References -- 2: Endocannabinoid System -- Introduction -- Purpose of the Endocannabinoid System -- Components of the Endocannabinoid System: Overview -- Endogenous Ligands: Endocannabinoids -- Endocannabinoids in Brief -- Synthesis of AEA and 2-AG -- Binding to Receptors (Extracellular and Intracellular) -- Transport Across the Plasma Membrane -- Intracellular Reservoirs Challenge Classic Understanding of Endocannabinoid On-Demand Synthesis -- Degradation of Endocannabinoids -- AEA Degradation -- 2-AG Degradation -- New Signaling Molecules Generated -- A Fine-Tuned Modulation System -- AEA and 2-AG in More Detail -- Anandamide (AEA) -- 2-Arachidonylglycerol (2-AG) -- Key Difference Between Endocannabinoids and Phytocannabinoids -- Endocannabinoid-Like Compounds: PEA, OEA, and Oleamide -- N-palmitoylethanolamide (PEA) and Oleoylethanolamide (OEA) -- Oleamide -- Cannabinoid Receptors -- Discovery of Cannabinoid Receptors -- Location of Cannabinoid Receptors -- Location of CB1 Receptors: Overview -- Neuroprotection -- CB1 Receptors in the CNS -- Glutamate and GABAergic Receptors -- CB1 Receptors Are More Abundant than Mu-Opioid Receptors -- CB1 Receptors and Cerebromicrovascular Endothelial Cells -- CB1 Receptors in Peripheral Nervous System and Periphery -- CB1 Receptors in the Peripheral Nervous System -- CB1 Receptors in the Gut -- CB1 Receptors in the Skin -- CB1 Receptors in the Liver -- Contrary Actions in the Periphery Compared with CNS: CB1 Receptors in Adipocytes -- Intracellular CB1 Receptors -- Different Isoforms of CB1 Receptors -- Functions of CB1 Receptors -- Functions of Mitochondrial CB1 Receptors.
CB2 Receptors -- CB2 Receptors and the Immune System -- CB2 Receptors in the Brain -- Unique Features of CB2 Receptors Compared with CB1 Receptors -- CB2 Receptors in Other Organs and Tissues -- CB2 Receptors in Skin -- Mechanisms of Action of the Endocannabinoid System (ECS) -- Classic Understanding of How the ECS Works in the Nervous System -- Complexity of the ECS: Multiple Signaling Pathway Involvement -- Biased Agonism -- Heteromers -- The ECS in Non-neural Cells -- ECS Signal Transmission Via Microvesicles -- Other Receptor Targets for Endocannabinoids -- TRPV1 Receptors -- Peroxisome Proliferator-Activated Receptors (PPARs) -- GPR55 Receptors -- The Endocannabinoid System in Neuroprotection -- Development and the Endocannabinoid System -- The ECS in Early Life -- The Adolescent Brain and the ECS -- Endocannabinoid System Dysfunction and Disease -- The Concepts of Endocannabinoid Tone and Endocannabinoid Deficiency -- Diseases in Which ECS Dysfunction Is Implicated -- Endocannabinoid System Dysfunction and Mental Health -- Omega 3 and 6 PUFAs in the Brain Health -- Diet and Importance of Omega 3 Fatty Acids for a Healthy ECS -- Studies Linking Omega 3 Deficiency and Mental Health Conditions -- Link Between ECS, Omega 3, and Omega 6 -- Why Are Omega 3 PUFAs Important for Functioning of the ECS? -- Why Are Dietary Sources of Long-Chain PUFAs Important? -- The Problem with the Western Diet -- Hemp Seeds Have a Very Good Ratio of Omega 6/Omega 3 PUFAs -- Conclusion -- References -- 3: The Endocannabinoid System, Stress, and Mental Health -- Introduction -- Key Brain Structures Involved in the Regulation of Stress -- Corticolimbic System -- Roles of the Components of the Corticolimbic System -- Hypothalamic-Pituitary-Adrenal (HPA) Axis -- Other Areas -- The Stress Response -- The Autonomic Stress Response. Sympathetic Nervous System Mechanisms of Action -- Parasympathetic Nervous System Neuroanatomical Connections -- Measurement of ANS Activity -- Neuroendocrine Stress Response -- The HPA Axis in Stress -- Measurement of Neuroendocrine Activity -- Sex Differences in the Stress Response System Along the HPA Axis -- When the Stress Response Becomes Pathological -- Stress and Inflammation -- How Does Stress Activate Inflammatory Changes? -- Endocannabinoid System and Stress Regulation -- Several Lines of Evidence that the ECS Is a Regulator of the Stress Response -- Bidirectional Relationship Between Stress and the ECS -- ECS and the Autonomic Nervous System Stress Response -- ECS, the Corticolimbic System, and the HPA Axis -- ECS and Regulation of the HPA Axis -- How Is the ECS Involved in Acute and Chronic Stress? -- Acute Stress -- Chronic Stress -- The Endocannabinoidome (Extended ECS) and Stress -- Genes, Stress, and the Endocannabinoid System -- Social Isolation -- Environmental Enrichment -- Early Life Stress and the Endocannabinoid System -- Early Life Stress, Corticolimbic System, and HPA Axis Development -- Stress Responsivity -- Findings from Animal Models -- Early Life Stress and Genetic Patterns in Humans -- Sex Differences in How Early Life Stress Affects the ECS -- The Gut and Stress -- The Gut Microbiome and Stress -- Microbiota Changes and Stress -- The Gut Regulates the HPA Axis -- Leaky Gut and Mental Health -- The Endocannabinoidome, the Gut, and Links to Mental Health -- Inflammation, the Gut, and the ECS -- Cannabis Exposure and Stress Responsivity -- Conclusion -- References -- 4: Overview of Medicinal Cannabis -- Introduction -- Definition of Medicinal Cannabis -- Taxonomy: What Is in a Name? -- Hemp -- Hemp Oil and Hemp Seed Oil -- Historical Use of Cannabis as Medicine -- Cannabis in China -- Cannabis in Other Ancient Cultures. Medicinal Cannabis in the Western World -- Regulations in the USA -- Active Constituents of Cannabis -- Where Are the Phytocannabinoids and Terpenes Found? -- Entourage Effect -- Cannabis Strains/Cultivars and Active Constituent Profiles -- Genes and Environmental Conditions -- A Word of Caution About Reductionism -- Phytocannabinoids: Overview -- Cannabidiol -- Therapeutic Actions of CBD -- What Conditions Can CBD Potentially Treat? -- Mechanisms of Action of CBD -- CBD Modulates Endocannabinoid Tone and Adenosine Tone -- CBD Modulates Multiple Signalling Systems -- Immunological and Anti-Inflammatory Effects -- Antioxidant Activity -- Anti-Bacterial Effect -- Cellular Benefits in the Central Nervous System -- Effects on Cardiovascular System -- Anti-Cancer Activity and Exosomes -- CBD Antagonism and Potentiation of THC -- Potentiation -- Antagonism -- Cannabidiolic Acid (CBDA) -- Tetrahydrocannabinol (THC) -- Therapeutic Actions of THC -- Mechanism of Action of THC -- Anti-Inflammatory Effects -- Anti-Ageing Effects -- THCA-A -- Other Phytocannabinoids -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Terpenes -- Actions of Terpenes -- Forms of Medicinal Cannabis -- Oils Are Not Oils -- A Gap in Our Knowledge: Lack of Studies in Whole Plant Extracts -- Superiority of Whole Spectrum CBD Over Pure CBD Isolate Demonstrated -- Dangers of Meta-Analyses -- Routes of Delivery and Pharmacokinetics -- Inhalation -- Oral Route -- Topical Route, Other Routes -- Bioavailability of CBD -- Bioavailability and Onset and Duration of Action of THC -- Safety -- Going Forward: The United Nations and the Single Convention -- Conclusion -- References -- 5: Anxiety -- Introduction -- Anxiety: Overview -- Types of Anxiety Disorder -- Associated Comorbidities -- Treatment of Anxiety -- Pathomechanisms Involved in Anxiety. Role of the Amygdala and Prefrontal Cortex in Anxiety -- Serotonin in Anxiety -- Noradrenergic System Involvement in Anxiety -- GABA Involvement in Anxiety -- Immune Dysfunction and Inflammation in Anxiety -- Inflammation and Anxiety -- Oxidative Stress -- Neurogenesis and the Hippocampus -- Adult Hippocampal Neurons and the Stress Response -- Neuritogenesis and Anxiety -- The Endocannabinoid System in Anxiety -- HPA Axis in Anxiety -- Endocannabinoids, Cannabinoid Receptors and Anxiety -- Enzymes of the ECS -- TRPV1 -- Scientific Evidence: CBD in the Treatment of Anxiety -- Mechanisms of Action of CBD in Anxiety -- CBD and the Serotonergic System -- CBD and the HPA -- CBD, Neurogenesis and Neuritogenesis -- CBD and Endocannabinoid Degradation -- CBD, Inflammation and Immune Function -- CBD, Sleep and Anxiety -- Animal Research: Efficacy of CBD in Anxiety -- Animal Models of Anxiety: Elevated Plus Maze -- Anxiety Studies in Rodents -- Animal Studies of Chronic CBD Administration -- Pure CBD Isolate and the Bell-Shaped Dose-Response Curve in Animal Studies -- Animal Study of Pure CBD Versus Whole Plant CBD -- Animal Research of CBDA in Anxiety -- Human Research: Efficacy of CBD in Anxiety -- Surveys -- Regional Cerebral Brain Flow Studies: Anxiety and CBD -- Observational Study: CBD and Anxiety -- Case Studies and Case Series -- Randomised Controlled Trials: CBD for Treatment of Anxiety -- Systematic Reviews: CBD and Anxiety Treatment -- Scientific Evidence: THC in the Treatment of Anxiety -- Preclinical Research: Effects of THC on Anxiety -- Anti-inflammatory Effects -- Human Research: Effects of Cannabis and THC on Anxiety -- Brain Imaging Studies -- Survey of Whole Plant Cannabis: Are Some Strains Better in Alleviating Anxiety? -- Observational Studies -- Randomised Controlled Trials -- Systematic Reviews. Does Adding CBD to THC Lower Its Anxiogenic Effect?. |
| Record Nr. | UNINA-9910508449403321 |
|
O'Brien Kylie
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||